{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:53:44Z","timestamp":1791305624299,"version":"4.3.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institute of Health","award":["R44 NS124443"],"award-info":[{"award-number":["R44 NS124443"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12028-026-02492-5","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:57:54Z","timestamp":1774371474000},"page":"553-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Novel Anti-Inflammatory Small Molecule MW189 Reduces Microglial Activation and Improves Functional Outcomes in a Murine Model of Subarachnoid Hemorrhage"],"prefix":"10.1007","volume":"45","author":[{"given":"Haichen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Faw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Cantillana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Neehouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna R.","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Shifrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J.","family":"Van Eldik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-8815","authenticated-orcid":false,"given":"Daniel T.","family":"Laskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2492_CR1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213511","author":"MM Ali","year":"2025","unstructured":"Ali MM, Rietkerken S, Schoones JW, Kruyt ND, Rinkel GJE, Wermer MJH, et\u00a0al. Risk factors of aneurysmal subarachnoid hemorrhage including analysis by sex: a systematic review and meta-analysis. Neurology. 2025. https:\/\/doi.org\/10.1212\/WNL.0000000000213511.","journal-title":"Neurology"},{"issue":"2","key":"2492_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/STROKEAHA.121.037147","volume":"53","author":"AMSML Fuentes","year":"2022","unstructured":"Fuentes AMSML, Amin-Hanjani S. Sex differences in cerebral aneurysms and subarachnoid hemorrhage. Stroke. 2022;53(2):624\u201333. https:\/\/doi.org\/10.1161\/STROKEAHA.121.037147.","journal-title":"Stroke"},{"issue":"12","key":"2492_CR3","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1136\/jnnp.2007.117655","volume":"78","author":"NK de Rooij","year":"2007","unstructured":"de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007;78(12):1365\u201372. https:\/\/doi.org\/10.1136\/jnnp.2007.117655.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2492_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11051259","author":"K Wu","year":"2023","unstructured":"Wu K, Chen L, Qiu Z, et\u00a0al. Protective effect and mechanism of Xbp1s regulating HBP\/O-GlcNAcylation through GFAT1 on brain injury after SAH. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11051259.","journal-title":"Biomedicines"},{"issue":"5","key":"2492_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamaneurol.2019.0006","volume":"76","author":"N Etminan","year":"2019","unstructured":"Etminan N, Chang HS, Hackenberg K, et\u00a0al. Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis. JAMA Neurol. 2019;76(5):588\u201397. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0006.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2492_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1578-1","volume":"16","author":"SH Ahn","year":"2019","unstructured":"Ahn SH, Savarraj JPJ, Parsha K, et\u00a0al. Inflammation in delayed ischemia and functional outcomes after subarachnoid hemorrhage. J Neuroinflammation. 2019;16(1):213. https:\/\/doi.org\/10.1186\/s12974-019-1578-1.","journal-title":"J Neuroinflammation"},{"issue":"5","key":"2492_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1161\/01.str.31.5.1054","volume":"31","author":"T Ingall","year":"2000","unstructured":"Ingall T, Asplund K, Mahonen M, Bonita R. A multinational comparison of subarachnoid hemorrhage epidemiology in the WHO MONICA stroke study. Stroke. 2000;31(5):1054\u201361. https:\/\/doi.org\/10.1161\/01.str.31.5.1054.","journal-title":"Stroke"},{"issue":"4","key":"2492_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s11883-008-0054-7","volume":"10","author":"W Gump","year":"2008","unstructured":"Gump W, Laskowitz DT. Management of post-subarachnoid hemorrhage vasospasm. Curr Atheroscler Rep. 2008;10(4):354\u201360. https:\/\/doi.org\/10.1007\/s11883-008-0054-7.","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"2492_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM198303173081103","volume":"308","author":"GS Allen","year":"1983","unstructured":"Allen GS, Ahn HS, Preziosi TJ, et\u00a0al. Cerebral arterial spasm--A controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308(11):619\u201324. https:\/\/doi.org\/10.1056\/NEJM198303173081103.","journal-title":"N Engl J Med"},{"issue":"6674","key":"2492_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/bmj.298.6674.636","volume":"298","author":"JD Pickard","year":"1989","unstructured":"Pickard JD, Murray GD, Illingworth R, et\u00a0al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298(6674):636\u201342. https:\/\/doi.org\/10.1136\/bmj.298.6674.636.","journal-title":"BMJ"},{"issue":"2","key":"2492_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12028-024-02182-0","volume":"42","author":"JA Llompart-Pou","year":"2025","unstructured":"Llompart-Pou JA, Perez-Barcena J, Godoy DA. Nimodipine in aneurysmal subarachnoid hemorrhage: are old data enough to justify its current treatment regimen? Neurocrit Care. 2025;42(2):334\u201340. https:\/\/doi.org\/10.1007\/s12028-024-02182-0.","journal-title":"Neurocrit Care"},{"issue":"3","key":"2492_CR12","doi-asserted-by":"publisher","DOI":"10.3171\/foc.2006.21.3.4","volume":"21","author":"RG Mesis","year":"2006","unstructured":"Mesis RG, Wang H, Lombard FW, et\u00a0al. Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. Neurosurg Focus. 2006;21(3):E4. https:\/\/doi.org\/10.3171\/foc.2006.21.3.4.","journal-title":"Neurosurg Focus"},{"issue":"10 Suppl","key":"2492_CR13","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1161\/STROKEAHA.110.595090","volume":"41","author":"DT Laskowitz","year":"2010","unstructured":"Laskowitz DT, Kolls BJ. Neuroprotection in subarachnoid hemorrhage. Stroke. 2010;41(10 Suppl):S79-84. https:\/\/doi.org\/10.1161\/STROKEAHA.110.595090.","journal-title":"Stroke"},{"issue":"1","key":"2492_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrneurol.2013.246","volume":"10","author":"RL Macdonald","year":"2014","unstructured":"Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10(1):44\u201358. https:\/\/doi.org\/10.1038\/nrneurol.2013.246.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"2492_CR15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1161\/STROKEAHA.110.597005","volume":"42","author":"RW Crowley","year":"2011","unstructured":"Crowley RW, Medel R, Dumont AS, et\u00a0al. Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke. 2011;42(4):919\u201323. https:\/\/doi.org\/10.1161\/STROKEAHA.110.597005.","journal-title":"Stroke"},{"issue":"3","key":"2492_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/bja\/aes264","volume":"109","author":"MJ Rowland","year":"2012","unstructured":"Rowland MJ, Hadjipavlou G, Kelly M, Westbrook J, Pattinson KT. Delayed cerebral ischaemia after subarachnoid haemorrhage: looking beyond vasospasm. Br J Anaesth. 2012;109(3):315\u201329. https:\/\/doi.org\/10.1093\/bja\/aes264.","journal-title":"Br J Anaesth"},{"issue":"4","key":"2492_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040497","volume":"17","author":"BP Lucke-Wold","year":"2016","unstructured":"Lucke-Wold BP, Logsdon AF, Manoranjan B, et\u00a0al. Aneurysmal subarachnoid hemorrhage and neuroinflammation: a comprehensive review. Int J Mol Sci. 2016;17(4):497. https:\/\/doi.org\/10.3390\/ijms17040497.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2492_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02085-3","volume":"18","author":"R Heinz","year":"2021","unstructured":"Heinz R, Brandenburg S, Nieminen-Kelha M, et\u00a0al. Microglia as target for anti-inflammatory approaches to prevent secondary brain injury after subarachnoid hemorrhage (SAH). J Neuroinflammation. 2021;18(1):36. https:\/\/doi.org\/10.1186\/s12974-021-02085-3.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"2492_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1227\/NEU.0b013e31828048ce","volume":"72","author":"C Muroi","year":"2013","unstructured":"Muroi C, Hugelshofer M, Seule M, et\u00a0al. Correlation among systemic inflammatory parameter, occurrence of delayed neurological deficits, and outcome after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2013;72(3):367\u201375. https:\/\/doi.org\/10.1227\/NEU.0b013e31828048ce.","journal-title":"Neurosurgery"},{"key":"2492_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00292","volume":"9","author":"AL de Oliveira Manoel","year":"2018","unstructured":"de Oliveira Manoel AL, Macdonald RL. Neuroinflammation as a target for intervention in subarachnoid hemorrhage. Front Neurol. 2018;9:292. https:\/\/doi.org\/10.3389\/fneur.2018.00292.","journal-title":"Front Neurol"},{"issue":"2","key":"2492_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bmcl.2006.10.028","volume":"17","author":"W Hu","year":"2007","unstructured":"Hu W, Ralay Ranaivo H, Roy SM, et\u00a0al. Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett. 2007;17(2):414\u20138. https:\/\/doi.org\/10.1016\/j.bmcl.2006.10.028.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"2492_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cpdd.795","volume":"10","author":"LJ Van Eldik","year":"2021","unstructured":"Van Eldik LJ, Sawaki L, Bowen K, et\u00a0al. First-in-human studies of MW01-6-189WH, a brain-penetrant, antineuroinflammatory small-molecule drug candidate: phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic studies in healthy adult volunteers. Clin Pharmacol Drug Dev. 2021;10(2):131\u201343. https:\/\/doi.org\/10.1002\/cpdd.795.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"2492_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s12028-023-01867-2","volume":"40","author":"R Avadhani","year":"2024","unstructured":"Avadhani R, Ziai WC, Thompson RE, et\u00a0al. Clinical trial protocol for BEACH: A phase 2a study of MW189 in patients with acute nontraumatic intracerebral hemorrhage. Neurocrit Care. 2024;40(2):807\u201315. https:\/\/doi.org\/10.1007\/s12028-023-01867-2.","journal-title":"Neurocrit Care"},{"key":"2492_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-020-02451-y","author":"NHV du Percie Sert","year":"2020","unstructured":"du Percie Sert NHV, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et\u00a0al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020. https:\/\/doi.org\/10.1186\/s12917-020-02451-y.","journal-title":"PLoS Biol"},{"issue":"4","key":"2492_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/svn-2018-000152","volume":"3","author":"J Liu","year":"2018","unstructured":"Liu J, Zhou G, Kolls BJ, et\u00a0al. Apolipoprotein E mimetic peptide CN-105 improves outcome in a murine model of SAH. Stroke Vasc Neurol. 2018;3(4):222\u201330. https:\/\/doi.org\/10.1136\/svn-2018-000152.","journal-title":"Stroke Vasc Neurol"},{"issue":"1","key":"2492_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12028-013-9944-9","volume":"20","author":"H Wang","year":"2014","unstructured":"Wang H, James ML, Venkatraman TN, et\u00a0al. pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH. Neurocrit Care. 2014;20(1):119\u201331. https:\/\/doi.org\/10.1007\/s12028-013-9944-9.","journal-title":"Neurocrit Care"},{"issue":"5","key":"2492_CR27","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1179\/016164102101200276","volume":"24","author":"A Parra","year":"2002","unstructured":"Parra A, McGirt MJ, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: methodological analysis. Neurol Res. 2002;24(5):510\u20136. https:\/\/doi.org\/10.1179\/016164102101200276.","journal-title":"Neurol Res"},{"issue":"2","key":"2492_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12028-020-01184-y","volume":"35","author":"H Wang","year":"2021","unstructured":"Wang H, Faw TD, Lin Y, et\u00a0al. Neuroprotective pentapeptide, CN-105, improves outcomes in translational models of intracerebral hemorrhage. Neurocrit Care. 2021;35(2):441\u201350. https:\/\/doi.org\/10.1007\/s12028-020-01184-y.","journal-title":"Neurocrit Care"},{"issue":"2","key":"2492_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/neu.1994.11.187","volume":"11","author":"RJ Hamm","year":"1994","unstructured":"Hamm RJ, Pike BR, O\u2019Dell DM, Lyeth BG, Jenkins LW. The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma. 1994;11(2):187\u201396. https:\/\/doi.org\/10.1089\/neu.1994.11.187.","journal-title":"J Neurotrauma"},{"key":"2492_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep33123","volume":"6","author":"KV Sawant","year":"2016","unstructured":"Sawant KV, Poluri KM, Dutta AK, et\u00a0al. Chemokine CXCL1 mediated neutrophil recruitment: role of glycosaminoglycan interactions. Sci Rep. 2016;6:33123. https:\/\/doi.org\/10.1038\/srep33123.","journal-title":"Sci Rep"},{"key":"2492_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2012.00006","volume":"5","author":"CL Dalgard","year":"2012","unstructured":"Dalgard CL, Cole JT, Kean WS, et\u00a0al. The cytokine temporal profile in rat cortex after controlled cortical impact. Front Mol Neurosci. 2012;5:6. https:\/\/doi.org\/10.3389\/fnmol.2012.00006.","journal-title":"Front Mol Neurosci"},{"key":"2492_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112306","author":"S Scheu","year":"2017","unstructured":"Scheu S, Ali S, Ruland C, Arolt V, Alferink J. The C-C chemokines CCL17 and CCL22 and their receptor CCR4 in CNS autoimmunity. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18112306.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2492_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.tins.2012.06.003","volume":"35","author":"M Li","year":"2012","unstructured":"Li M, Hale JS, Rich JN, Ransohoff RM, Lathia JD. Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. Trends Neurosci. 2012;35(10):619\u201328. https:\/\/doi.org\/10.1016\/j.tins.2012.06.003.","journal-title":"Trends Neurosci"},{"key":"2492_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2014.00065","volume":"8","author":"A Guyon","year":"2014","unstructured":"Guyon A. CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front Cell Neurosci. 2014;8:65. https:\/\/doi.org\/10.3389\/fncel.2014.00065.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"2492_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/brain\/aww271","volume":"140","author":"S Capsoni","year":"2017","unstructured":"Capsoni S, Malerba F, Carucci NM, et\u00a0al. The chemokine CXCL12 mediates the anti-amyloidogenic action of painless human nerve growth factor. Brain. 2017;140(1):201\u201317. https:\/\/doi.org\/10.1093\/brain\/aww271.","journal-title":"Brain"},{"issue":"1","key":"2492_CR36","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.124.002334","volume":"392","author":"H Wang","year":"2025","unstructured":"Wang H, Dingledine RJ, Myers SJ, et\u00a0al. Clinical development of the GluN2B-selective NMDA receptor inhibitor NP10679 for the treatment of neurologic deficit after subarachnoid hemorrhage. J Pharmacol Exp Ther. 2025;392(1):100046. https:\/\/doi.org\/10.1124\/jpet.124.002334.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2492_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/1567205053585828","volume":"2","author":"W Hu","year":"2005","unstructured":"Hu W, Ralay Ranaivo H, Craft JM, Van Eldik LJ, Watterson DM. Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer\u2019s disease-related mouse model. Curr Alzheimer Res. 2005;2(2):197\u2013205. https:\/\/doi.org\/10.2174\/1567205053585828.","journal-title":"Curr Alzheimer Res"},{"issue":"6","key":"2492_CR38","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1097\/ALN.0b013e318253a02a","volume":"116","author":"ML James","year":"2012","unstructured":"James ML, Wang H, Cantillana V, et\u00a0al. TT-301 inhibits microglial activation and improves outcome after central nervous system injury in adult mice. Anesthesiology. 2012;116(6):1299\u2013311. https:\/\/doi.org\/10.1097\/ALN.0b013e318253a02a.","journal-title":"Anesthesiology"},{"issue":"2","key":"2492_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149451","volume":"11","author":"AD Bachstetter","year":"2016","unstructured":"Bachstetter AD, Zhou Z, Rowe RK, et\u00a0al. MW151 inhibited IL-1\u03b2 levels after traumatic brain injury with no effect on microglia physiological responses. PLoS ONE. 2016;11(2):e0149451. https:\/\/doi.org\/10.1371\/journal.pone.0149451.","journal-title":"PLoS ONE"},{"issue":"6","key":"2492_CR40","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3171\/jns.1999.90.6.1011","volume":"90","author":"G Lanzino","year":"1999","unstructured":"Lanzino G, Kassell NF, Dorsch NW, et\u00a0al. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa. J Neurosurg. 1999;90(6):1011\u20137. https:\/\/doi.org\/10.3171\/jns.1999.90.6.1011.","journal-title":"J Neurosurg"},{"issue":"6","key":"2492_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/s1052-3057(97)80039-0","volume":"6","author":"SL Smith","year":"1997","unstructured":"Smith SL, Larson PG, Hall ED. A comparison of the effects of tirilazad on subarachnoid hemorrhage-induced blood-brain barrier permeability in male and female rats. J Stroke Cerebrovasc Dis. 1997;6(6):389\u201393. https:\/\/doi.org\/10.1016\/s1052-3057(97)80039-0.","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02492-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-026-02492-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02492-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:10:48Z","timestamp":1791303048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-026-02492-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2492"],"URL":"https:\/\/doi.org\/10.1007\/s12028-026-02492-5","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.V.E. is an inventor on the patents covering MW189. L.V.E. and V.S. are founders of ImmunoChem Therapeutics, LLC, a Northwestern spin\u2010out formed to commercialize MW189. Northwestern University and the University of Kentucky might benefit if MW189 is successful commercially. D.T.L. serves as a consultant for ImmunoChem. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were conducted under the approval of the Duke University Institutional Animal Care and Use Committee (protocol no. A181-23-09).","order":2,"name":"Ethics","label":"Ethical Approval\/ Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}